-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CVHbJM2rJ5QDVxbrDtgahRQosILj0jSb4TkdZViRV52RCkn5SjYIFwATjI5dhRHL D+f3jxiN4rBRKfhgsuCo8A== 0000950133-05-002545.txt : 20050611 0000950133-05-002545.hdr.sgml : 20050611 20050606172616 ACCESSION NUMBER: 0000950133-05-002545 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050606 DATE AS OF CHANGE: 20050606 GROUP MEMBERS: BIOTECH GROWTH N.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: EYETECH PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001115285 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134104684 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-80385 FILM NUMBER: 05881293 BUSINESS ADDRESS: STREET 1: 3 TIMES SQUARE STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 2128243100 MAIL ADDRESS: STREET 1: 3 TIMES SQUARE STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 SC 13G/A 1 w09711sc13gza.htm SCHEDULE 13G, AMENDMENT NO.1 sc13gza
 

 
 

United States
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

EYETECH PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

302297106

(CUSIP Number)

May 24, 2005

(Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
o   Rule 13d 1(b)
þ   Rule 13d 1(c)
o   Rule 13d 1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed “ for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

Page 1 of 8

 

  CUSIP No: 302297106
 
        
               
1
NAMES OF REPORTING PERSONS
 
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) N/A
 
  
 
BB Biotech AG
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
              
 
     
(a)		    þ  
 
 
 
(b)
    o  
3
SEC USE ONLY
               
 
              
4
CITIZENSHIP OR PLACE OF ORGANIZATION
               
 
Switzerland
          
NUMBER OF SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
SOLE VOTING POWER
             
 
0
        
6 SHARED VOTING POWER
             
  1,627,194        
7
SOLE DISPOSITIVE POWER
             
 
0
        
8
SHARED DISPOSITIVE POWER
         
               
 
1,627,194
      
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
              
 
1,627,194
          
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
              
 
 
 
         o  
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
  
 
3.8%
 
 
    
12
TYPE OF REPORTING PERSON*
 
    
   
 
 HC,CO

Page 2 of 8

 

  CUSIP No: 302297106
 
        
               
1
NAMES OF REPORTING PERSONS
 
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) N/A
 
  
 
Biotech Growth N.V.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
              
 
     
(a)		    þ  
 
 
 
(b)
    o  
3
SEC USE ONLY
               
 
              
4
CITIZENSHIP OR PLACE OF ORGANIZATION
               
 
Netherlands Antilles
          
NUMBER OF SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
SOLE VOTING POWER
             
 
0
        
6 SHARED VOTING POWER
             
  1,627,194        
7
SOLE DISPOSITIVE POWER
             
 
0
        
8
SHARED DISPOSITIVE POWER
         
               
 
1,627,194
      
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
              
 
1,627,194
          
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
              
 
 
 
         o  
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
  
 
3.8%
 
 
    
12
TYPE OF REPORTING PERSON*
 
    
   
 
 CO

Page 3 of 8

 

                     
Item 1
                    
    1 (a)   Name of Issuer:                    Eyetech Pharmaceuticals, Inc.                   
    1 (b)   Address of Issuer’s Principal Executive Offices:        
 
                    
          3 Times Square, 12th Fl, New York, NY 10036        
                   
 
                    
Item 2
                    
    2 (a)   Name of Person Filing: BB Biotech AG (“BB Biotech”), on behalf of Biotech Growth N.V. (“BioGrowth”), its wholly-owned subsidiary and record owner of the securities.        
    2 (b)   Address of Principal Business Office or, if none, Residence:        
 
                    
          BB Biotech AG:     Vordergasse 3, CH-8200 Schaffhausen, Switzerland        
 
                    
          Biotech Growth N.V.:     De Ruyterkade 62, Willemstad, Curacao Netherlands Antilles    
 
                    
    2 (c)   Citizenship:                    Switzerland                   
    2 (d)   Title of Class of Securities:                    Common Stock                   
    2 (e)   CUSIP Number                    302297106                       

Item 3

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

         
a.
  o   Broker or Dealer registered under Section 15 of the Act.
 
        
b.
  o   Bank as defined in Section 3(a)(6) of the Act.
 
        
c.
  o   Insurance company as defined in Section 3(a)(19) of the Act.
 
        
d.
  o   Investment company registered under section 8 of the Investment Company Act of 1940.
 
        
e.
  o   An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
 
        
f.
  o   An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
 
        
g.
  o   A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
 
        
h.
  o   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
        
i.
  o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
 
        
j.
  o   Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Page 4 of 8

 

Item 4. Ownership

     Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

         
(a) Amount beneficially owned:
                1,627,194                
(b) Percent of class:
                    3.8%                    
(c) Number of shares as to which the person has:
        
(i) Sole power to vote or to direct the vote
     0  
 
      
(ii) Shared power to vote or to direct the vote
     1,627,194  
 
      
(iii) Sole power to dispose or to direct the disposition of
     0  
 
      
(iv) Shared power to dispose or to direct the disposition of
     1,627,194  
 
      

Item 5. Ownership of Five Percent or Less of a Class

     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: þ

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     This statement is filed jointly by BB Biotech and BioGrowth. BioGrowth is a
     wholly-owned subsidiary of BB Biotech.                    

Item 8. Identification and Classification of Members of the Group

N/A

Item 9. Notice of Dissolution of Group

N/A

Page 5 of 8

 

Item 10. Certification

     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 6 of 8

 

SIGNATURES

     After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

             
            BB Biotech AG
 
            
Date:
  June 3, 2005   By:    /s/ Pascal Schmucki
           
          Signatory Authority
 
            
      Name:   Pascal Schmucki
           
      Title:   Signatory Authority
           
 
            
Date:
  June 3, 2005   By:    /s/ Roland Maier
           
          Signatory Authority
 
            
      Name:   Roland Maier
           
      Title:   Signatory Authority
           
 
            
          Biotech Growth N.V.
 
            
Date:
  June 3, 2005   By:    /s/ Pascal Schmucki
           
          Signatory Authority
 
            
      Name:   Pascal Schmucki
           
      Title:   Signatory Authority
           
 
            
Date:
  June 3, 2005   By:    /s/ Roland Maier
           
          Signatory Authority
 
            
      Name:   Roland Maier
           
      Title:   Signatory Authority
           

Page 7 of 8

 

Exhibit A

Joint Filing Statement

     Pursuant to Rule 13d-1(f)(1), we, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

             
            BB Biotech AG
 
            
Date:
  June 3, 2005   By:    /s/ Pascal Schmucki
           
          Signatory Authority
 
            
      Name:   Pascal Schmucki
           
      Title:   Signatory Authority
           
 
            
Date:
  June 3, 2005   By:    /s/ Roland Maier
           
          Signatory Authority
 
            
      Name:   Roland Maier
           
      Title:   Signatory Authority
           
 
            
          Biotech Growth N.V.
 
            
Date:
  June 3, 2005   By:    /s/ Pascal Schmucki
           
          Signatory Authority
 
            
      Name:   Pascal Schmucki
           
      Title:   Signatory Authority
           
 
            
Date:
  June 3, 2005   By:    /s/ Roland Maier
           
          Signatory Authority
 
            
      Name:   Roland Maier
           
      Title:   Signatory Authority
           

Page 8 of 8

-----END PRIVACY-ENHANCED MESSAGE-----